Karen L. Price, Ph.D.

Adjunct Professor of Statistical Science
High Res Photo

Adjunct Professor of Statistical Science


  • Ph.D., Statistics, Baylor University, 2001
  • M.A., Statistics, Baylor University, 1999
  • B.A,, Mathematics, Baylor University, 1997


Karen Price is a Research Advisor at Eli Lilly and Company. Karen received her Ph.D. in Biostatistics in 2001 from Baylor University. She is currently leading the Bayesian methods efforts within the Advanced Analytics/Science Driven Adaptive Program team. She chairs the DIA Bayesian Scientific Working Group, which includes members in Industry, Regulatory, and Academia. The group's mission is to ensure that Bayesian methods are well-understood, accepted, and broadly utilized throughout medical product development. Her research interests include Bayesian meta-analysis, Bayesian methods for safety signal detection and evaluation, and Bayesian design and analysis of clinical trials.

Selected Publications

Hong H, Fu H, Price K, and Carlin B. Incorporation of individual-patient data in network meta-analysis for multiple continuous endpoints, with application to diabetes treatment. Statistics in Medicine, 2015.

Xia A and Price K. Bayesian Applications for Drug Safety Evaluation. Chapter in Quantitative Evaluation of Safety in Drug Development. CRC Press, edited by Jiang and Xia, 2015.

Liu-Siefert H, Siemers E, Price K, Han B, Selzler K, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R, and the Alzheimer's Disease Neuroimaging Initiative. "Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease." Journal of Alzheimer's Disease, 47: 205-214, 2015.

Liu-Seifert H, Simers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. "Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia." Journal of Alzheimer's Disease. 43: 949-955, 2015.

Price K and LaVange L. Bayesian Methods in Medical Product Development and Regulatory Review. Pharmaceutical Statistics, 2014.

Price K, Xia A, Lakshminarayanan M, Madigan D, Manner D, Scott J, Stamey J, and Thompson L. Bayesian methods for design and analysis of safety trials. Pharmaceutical Statistics, 2014.

Ohlssen D, Price K, Xia A, Hong H, Kerman J, Fu H, Quartey G, Heimann C, Ma H, Carlin B. Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis. Pharmaceutical Statistics, 2014.

Stamey J, Beavers D, Faries D, Price K, Seaman J. Bayesian modeling of cost-effectiveness studies with unmeasured confounding: a simulation study. Pharmaceutical Statistics, 2014.

Fu H, Price K, Nilsson M, and Ruberg S. Identifying Potential Adverse Events Dose-Response Relationships via Bayesian Indirect and Mixed Treatment Comparison Models. Journal of Biopharmaceutical Statistics.

Bennett M, Crowe B, Price K, Stamey J, Seaman J. Comparison of Bayesian and Frequentist Meta-Analytical Approaches for Analyzing Time to Event Data. Journal of Biopharmaceutical Statistics.

Myers J, Wielage R, Han B, Price K, Gahn J, Paget M-A, Happich M. The Efficacy of Duloxetine, Non-sterodial Anti-inflammatory Drugs, and Opioids in Osteoarthritis: A Systematic Literature Review and Meta-analysis. Submitted to Osteoarthritis and Cartilage.

Faries D, Peng X, Pawaskar M, Price K, Stamey J, and Seaman J. Evaluating the Impact of Unmeasured Confounding with Internal Validation Data: An Example Cost Evaluation in Type 2 Diabetes. Accepted Value In Health.

vMehta N, Sheetz M, Price K, Comiskey L, Amruita S, Iqbal N, Mohler E, Reilly M. Selective PKC b Inhibition with Ruboxistaurin and Endothelial Function in Type-2 Diabetes, submited to Diabetes Care.

Tesfaye S, Tanden R, Bastyr EJ III, Kles KA, Skljarevski V, Price KL, Ruboxistaurin Study Group. Factors the Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials. Diabetes Care. 2007; 30: 2626-2632.

Kincaid J, Price K, Jimenez M, Skljarevski V. Correlation of Vibratory Quantitative Sensory Testing and Nerve Conduction Studies in Patients with Diabetes. Muscle and Nerve. 2007; 36: 821-827.

McGill JB, King GL, Berg PH, Price KL, Kles KA, Bastyr EJ, and Hyslop DL. Clinical safety of the selective PKC-ß inhibitor, Ruboxistaurin. Expert Opinion on Drug Safety. 2006; 5(6): 835-845.

King GL, McGill JB, Hyslop DL, Berg PH, Price KL, Kles KA, Bastyr EJ, Vignati L. Clinical Safety of the PKC-ß Inhibitor, Ruboxistaurin in Patients with Diabetic Microvascular Complications. Diabetologia 2006; 49(suppl 1): 657.